Sh. Sharifi , K. Saberi , M. Rahmanian , A. Bakhshandeh , Volume 2, Issue 4 (10-2023)
Abstract
Aims: Despite many developments in the health care of cardiac surgery patients, yet 5%–30% of them may become challenged due to renal dysfunction, delirium, and arrhythmia. Eliminating or reducing these unwanted outcomes is likely to improve the prognosis of them. The purpose of the current study was to investigate the outcome of the administration of DEX in patients undergoing cardiac surgeries. Materials & Methods: The data from patents who underwent coronary artery bypass grafting (CABG) without a valve, CABG with valve surgery, and valve-only surgery from August to November 2018 were analyzed. A total of 51 patients were eligible for our study after extraction. For the DEX group, the infusion of DEX was started 10 min before anesthesia induction in a 0.2–0.6 µg/Kg/h rate. And the same amount of normal saline (0.9%) was infused for the control group. The infusion was continued post-operatively until extubation (maximum for 24h). The patients were compared primarily for Acute Kidney Injury (AKI), delirium, new-onset atrial fibrillation (AF) rhythm. Findings: There was no significant difference between groups for demographic data. One patient (16.7%) from the DEX group and five patients (83.3%) from the control group revealed an AF rhythm after surgery (p=0.009). No patient faced delirium. Seven patients seemed to be AKI, of which five (71.4%) were in the DEX group and two (28.6%) were in the control group (p>0.05). Conclusion: There might be a meaningful reduction of new-onset AF rhythm in adult patients who use DEX after cardiac surgeries.
